Retatrutide: The Unapproved Weight-Loss Drug Already Flooding the Black Market
A weight-loss injection that no health regulator on Earth has approved for human use is already being sold out of gyms, beauty salons, hairdressers — and even by street vendors — in the United Kingdom. The drug is called retatrutide, nicknamed "Reta" by the people using it, and its unauthorised, counterfeit versions have spread faster than the clinical trials meant to prove whether it's even safe.
Pharmacists, doctors and regulators say this may be the first time in memory that fake versions of an experimental drug have become this widely available before the real medicine has cleared a single regulatory approval anywhere in the world.
What Is Retatrutide and Why Is Everyone Talking About It
Retatrutide is being developed by the American pharmaceutical giant Eli Lilly, the company behind the diabetes and weight-loss drugs Mounjaro and Zepbound. Unlike currently approved GLP-1 drugs — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro) — which act on one or two hormone receptors, retatrutide targets three at once. That's earned it the nickname "triple G":
- GLP-1 – slows stomach emptying, signals fullness to the brain, and helps regulate blood sugar
- GIP – boosts insulin release and improves insulin sensitivity, working alongside GLP-1 to reduce appetite
- Glucagon – increases resting energy expenditure, helping the body burn more calories and reduce liver fat
In Eli Lilly's Triumph-4 phase 3 trial, the highest weekly dose of retatrutide produced an average body-weight reduction of close to 29% over 68 weeks — surpassing the roughly 21% average seen in late-stage trials of tirzepatide. That kind of result, on par with what some patients achieve through bariatric surgery, is a big part of why interest in the drug has outpaced the science.
No Approval Anywhere — But a Booming Black Market
Retatrutide has not been cleared for human use by any drug regulator globally. Eli Lilly says it doesn't plan to file for U.S. FDA approval until sometime next year, and with a review process that typically takes around a year, the drug is unlikely to be legally available in the United States before late 2027. In the UK, approval depends on the Medicines and Healthcare products Regulatory Agency (MHRA) and could stretch to 2028.
None of that has stopped a thriving underground trade. Vials labelled "retatrutide" are being sold through TikTok, Instagram, personal trainers, beauty salons and even informal street sellers. Buyers typically have no way of confirming what's actually inside the vial, how it was manufactured, or whether the dosage matches what's printed on the label.
Sehar Shahid, director and pharmacist at a 24-hour pharmacy, says people are essentially injecting themselves with an unregulated substance while assuming it's safe — a practice she describes as having become so normalised that buyers openly discuss suppliers online.
Real Health Risks, Real Hospital Visits
Doctors report a growing number of otherwise healthy, young patients arriving at hospitals with nausea, vomiting, diarrhoea, and in some cases kidney complications after using black-market retatrutide, according to endocrinologist Professor Donal O'Shea. He notes that some personal trainers aren't just supplying the drug to clients — they're administering the injections themselves, leaving patients unaware of exactly what or how much they've received.
One user, 20-year-old Tom Davies from Brighton, ordered counterfeit retatrutide from a supplier in China after friends at his gym recommended it. He accidentally took eight times the intended dose and described 72 hours of severe diarrhoea and nausea so intense he thought he would need emergency care.
Separately, U.S. data compiled by America's Poison Centers showed a sharp rise in retatrutide-related exposure calls in early 2026 — averaging 95 cases a month, up 265% from late 2025 — with symptoms including fainting and rapid heart rate. In Australia, health authorities linked a counterfeit retatrutide vial to a case of severe liver injury, reportedly tied to a contaminated batch, according to a report by ABC Australia.
Some users also report side effects not typically seen in Eli Lilly's own clinical data, including brain fog, reduced libido, and an inability to feel pleasure — differences researchers say may reflect inconsistent or contaminated black-market products rather than the drug itself.
Not every account is negative. Some users, including UK-based Lisa King, say months of use eased sugar cravings and helped with symptoms she associates with a metabolic condition. But medical experts caution that individual anecdotes don't establish safety, and what works — or doesn't — for one user offers no guarantee for another.
Eli Lilly Is Fighting Back
Eli Lilly has spent close to a decade developing retatrutide and is now pushing back hard against the counterfeit trade threatening both patient safety and its own product. The company says it has reported more than 14,000 websites, advertisements and social media posts it believes are illegally promoting the drug.
In August 2026, Lilly escalated the fight further, filing six lawsuits against medical spas, compounding pharmacies and online sellers — including Striker Pharmacy, Aesthetic Envy, Astra Peptides, Legendary Peptides, Texas Peptides and Lone Star Peptide — accusing them of marketing retatrutide as a weight-loss "hack" while falsely labelling products "for research use only." The company is also pressing credit card processors and social media platforms to cut off payment and advertising access for these sellers.
Adding to the complexity, Lilly is separately locked in a regulatory dispute over whether retatrutide should be classified as a biologic or a conventional drug — a distinction that would grant 12 years of market exclusivity and block legal compounding even during future shortages. Courts have so far sent the question back to the FDA for further review.
In the UK, the MHRA says it has seized multiple unlicensed products claiming to be retatrutide during raids over the past year, including one factory raid in Northampton that turned up more than 2,000 unlicensed pens. The agency says it continues working to disrupt illegal imports and distribution, though supply clearly hasn't stopped.
The Bigger Picture: A Pattern With GLP-1 Drugs
This isn't the first time demand has outrun supply and regulation in the GLP-1 category. Earlier shortages of Ozempic, Mounjaro, Wegovy and Zepbound already fuelled a rise in both legally and illegally compounded versions of approved drugs. What's different with retatrutide is that, unlike those cases, there is no approved version at all — meaning every dose on the black market is, by definition, unverified.
Professor O'Shea argues the answer isn't to dismiss the entire drug class. GLP-1 medicines, he says, represent a genuine advance in obesity treatment and in scientific understanding of appetite and craving regulation in the brain — but that doesn't extend to unregulated copies with unknown contents.
Doctors are also being urged to change how they talk to patients about this. Dr Sahira Dar, president of the British Islamic Medical Association, says healthcare workers should ask patients about black-market drug use without judgement, so people feel able to disclose what they've actually taken — information that could be critical in an emergency.
FAQs
Is retatrutide approved for use anywhere?
No. As of September 2026, no drug regulator in the world — including the U.S. FDA or the UK's MHRA — has approved retatrutide for human use. It remains in clinical trials.
Why is it called "triple G"?
Because it targets three hormone receptors — GLP-1, GIP and glucagon — unlike currently approved drugs like Ozempic or Mounjaro, which act on one or two.
When might retatrutide become legally available?
Eli Lilly plans to apply for FDA approval in early 2027, with U.S. availability unlikely before late 2027. UK approval, dependent on the MHRA, could take until 2028.
Why are people risking counterfeit versions?
Early trial data shows retatrutide could deliver greater weight loss than any currently approved obesity drug, driving demand from people unwilling to wait years for approval.
What are the risks of black-market retatrutide?
Reported problems include severe nausea, vomiting, diarrhoea, kidney issues, fainting, rapid heart rate, and at least one documented case of liver injury. Since these products are unregulated, their actual contents, purity and dosage cannot be verified.
